PHARMACEUTICAL PREPARATIONS OPHTHALMOLOGICAL USE

Brand Owner (click to sort) Address Description
MYSOL Novaliq GmbH Im Neuenheimer Feld 515 Heidelberg D-69120 Germany Pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for dermatologic use; medicinal preparations and substances for ophtalmological and dermatological use;
NAZIL LABORATORIOS SOPHIA, S.A. DE C.V. Av. Paseo Del Norte 5255 Guadalajara Technology Park Zapopan, Jalisco C.P. 45010 Mexico pharmaceutical preparations for ophthalmological use;The wording NAZIL has no meaning in a foreign language.;
NUTROF LABORATOIRES THEA Zone Industrielle du Brézet 12, rue Louis Blériot CLERMONT-FERRAND 63100 France Pharmaceutical preparations for ophthalmological use; Ophthalmic and ophthalmological preparations; Nutritional supplements; Vitamin preparations; Nutritional supplements for medical purposes; Mineral food supplements;
OPTIPREX XOMA TECHNOLOGY LTD. Clarendon House, 2 Church Street Hamilton HM11 Bermuda Pharmaceutical preparations for ophthalmological use;
YODA Novaliq GmbH Im Neuenheimer Feld 515 Heidelberg D-69120 Germany pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for use in dermatology; medicinal preparations and substances for ophthalmological use; medicinal preparations and substances for dermatological use;
ZOLANDRA Novaliq GmbH Im Neuenheimer Feld 515 Heidelberg D-69120 Germany Pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for dermatological use; medicinal preparations and substances for ophthalmological and dermatological use;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.